About Us
Tetra Health was founded in 2018 on the principles of improving health outcomes and creating accessibility.
Tetra Health is a leading Australian clinic network that facilitates responsible access to medicinal cannabis medicines for patients in every State and Territory in Australia.
As a specialist in this area of medicine, Tetra Health accepts patient referrals, providing ongoing support and patient monitoring from specialist nurses and Authorised Prescribers.
Tetra’s proprietary patient engagement and monitoring solution enables secure patient onboarding, automation of Special Approval Scheme and Therapeutic Goods Administration applications, better patient management and continuing care through Tetra’s specialist nurses and Authorised Prescribers.
The Tetra Health Difference
personalised care
Tetra Doctors prescribe a wide range of medications available in Australia. Every patient is unique, so that means we find the right medication(s) for you.
trusted provider
As leader in patient centric care, we are proud to offer Australian patients 5-star support. Tetra believes in full transparency and have no hidden fees.
easy process
We obtain TGA approvals within 48 hours after your Doctor Appointment. Our consults are held virtually or in clinic – whatever is most convenient to you.
experienced team
When you choose Tetra, you are choosing ongoing support and expertise. Our medical team is beside you every step of the way, so you get the best possible health outcomes.
Medical Advisory Board
Professor Andrew McLachlan is the Head of School and Dean of Pharmacy in the Sydney Pharmacy School and a Member of the Order of Australia. He is currently the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing. He is the former Professor of Pharmacy (Aged Care) (2006-2018) in the then Faculty of Pharmacy and at Concord Hospital’s Centre for Education and Research on Ageing.
Andrew is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research and high quality clinical trial evidence into real-world practice.
Dr Mona Singh completed her undergraduate study of Medicine in India in 2005, before completing her training in the UK in 2012. Since then, she has been practicing as a GP and was admitted to the Royal Australian College of General Practitioners in 2013. Mona takes an integrative and holistic approach to her practice, which is reflected in her thorough and empathetic approach to her patients.
Mona is a medical editor at CESPHN, and a member of their Clinical Advisory Committee. Mona is also Medical Director of BUPA, and a BPUA (MBVS) Education Committee Member.
MBBS, MRCGP, FRACGP 
Professor Stephen Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers and pharmacology. He is a medical oncologist at the Northern Cancer Institute and Royal North Shore Hospital, Director of Cancer Services at Northern Sydney Local Health District and Professor of Medicine at the University of Sydney.
Stephen is Head of the NSW committee of the RACP and is Oncology Advisor to the Department of Veterans Affairs as well as a Member of the Repatriation Pharmaceutical Review Committee.
Associate Professor Kellie Charles is a cancer pharmacologist with a research interest in the interactions between inflammation, the immune system and cancer chemotherapy outcomes. She is the Head of the Cancer Therapeutics Research Laboratory at the University of Sydney and 15 years of clinical and translational research experience.
Dr Samuel Banister is a Senior Research Fellow in the School of Chemistry at The University of Sydney. He brings more than 10 years of experience drug discovery and cannabinoid science to the role. Dr Banister has recently returned to Australia after completing postdoctoral training in radiochemistry, positron emission tomography (PET) imaging, and drug development at Stanford University. His research is centred on the use of cannabinoids for the treatment of epilepsy, affective disorders, and pain.
Previous
Next
Professor Andrew McLachlan is the Head of School and Dean of Pharmacy in the Sydney Pharmacy School and a Member of the Order of Australia. He is currently the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing. He is the former Professor of Pharmacy (Aged Care) (2006-2018) in the then Faculty of Pharmacy and at Concord Hospital’s Centre for Education and Research on Ageing.
Andrew is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research and high quality clinical trial evidence into real-world practice.
Dr Mona Singh completed her undergraduate study of Medicine in India in 2005, before completing her training in the UK in 2012. Since then, she has been practicing as a GP and was admitted to the Royal Australian College of General Practitioners in 2013. Mona takes an integrative and holistic approach to her practice, which is reflected in her thorough and empathetic approach to her patients.
Mona is a medical editor at CESPHN, and a member of their Clinical Advisory Committee. Mona is also Medical Director of BUPA, and a BPUA (MBVS) Education Committee Member.
MBBS, MRCGP, FRACGP
Professor Stephen Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers and pharmacology. He is a medical oncologist at the Northern Cancer Institute and Royal North Shore Hospital, Director of Cancer Services at Northern Sydney Local Health District and Professor of Medicine at the University of Sydney.
Stephen is Head of the NSW committee of the RACP and is Oncology Advisor to the Department of Veterans Affairs as well as a Member of the Repatriation Pharmaceutical Review Committee.
Associate Professor Kellie Charles is a cancer pharmacologist with a research interest in the interactions between inflammation, the immune system and cancer chemotherapy outcomes. She is the Head of the Cancer Therapeutics Research Laboratory at the University of Sydney and 15 years of clinical and translational research experience.
Dr Samuel Banister is a Senior Research Fellow in the School of Chemistry at The University of Sydney. He brings more than 10 years of experience drug discovery and cannabinoid science to the role. Dr Banister has recently returned to Australia after completing postdoctoral training in radiochemistry, positron emission tomography (PET) imaging, and drug development at Stanford University. His research is centred on the use of cannabinoids for the treatment of epilepsy, affective disorders, and pain.
Previous
Next
